HighTower Advisors
RNAC icon

HighTower Advisors’s Cartesian Therapeutics RNAC Stock Holding History

HighTower Advisors’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-840
Closed -$17K – 3941
2023
Q4 		$17K Hold
840
– – ﹤0.01% 3408
2023
Q3 		$26K Hold
840
– – ﹤0.01% 3307
2023
Q2 		$28K Buy
+840
New +$30.1K ﹤0.01% 3225

Other funds holding RNAC

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HighTower Advisors's RNAC Position: Q1 2024 in Review

HighTower Advisors sold out of Cartesian Therapeutics (RNAC) in Q1 2024, closing a stake of 840 shares — an estimated $17K sold.

HighTower Advisors first reported a position in RNAC in Q2 2023 and held it in 3 quarters. The position peaked at $28K in Q2 2023. 69 funds tracked by Wall St. Rank hold RNAC as of Q1 2024.

  • HighTower Advisors reported no remaining Cartesian Therapeutics position as of Q1 2024 after selling out during the quarter.
  • HighTower Advisors sold 840 Cartesian Therapeutics shares in Q1 2024, an estimated $17K.
  • HighTower Advisors first reported a position in Cartesian Therapeutics in Q2 2023 and held it in 3 quarters.
  • HighTower Advisors's Cartesian Therapeutics position peaked at $28K in Q2 2023.
  • 69 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2024.

Based on HighTower Advisors's 13F filing for Q1 2024, filed 6 May 2024.